Loading...
A256940 logo

Keeps Biopharma Inc.KOSDAQ:A256940 Stock Report

Market Cap ₩128.7b
Share Price
₩6.41k
₩13k
50.7% undervalued intrinsic discount
1Y-60.6%
7D-2.7%
Portfolio Value
View

Keeps Biopharma Inc.

KOSDAQ:A256940 Stock Report

Market Cap: ₩128.7b

Keeps Biopharma (A256940) Stock Overview

Engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. More details

A256940 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis


A256940 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Keeps Biopharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Keeps Biopharma
Historical stock prices
Current Share Price₩6,410.00
52 Week High₩22,150.00
52 Week Low₩5,900.00
Beta1.19
1 Month Change-33.92%
3 Month Change-25.03%
1 Year Change-60.58%
3 Year Change-38.66%
5 Year Change-63.89%
Change since IPO8.34%

Recent News & Updates

Analysis Article Jan 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Dec 01

Keeps Biopharma Inc.'s (KOSDAQ:256940) Shares Not Telling The Full Story

There wouldn't be many who think Keeps Biopharma Inc.'s ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 1.3x is...

Recent updates

Analysis Article Jan 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Dec 01

Keeps Biopharma Inc.'s (KOSDAQ:256940) Shares Not Telling The Full Story

There wouldn't be many who think Keeps Biopharma Inc.'s ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 1.3x is...
Analysis Article Sep 06

Is Keeps Biopharma (KOSDAQ:256940) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Aug 01

Not Many Are Piling Into Keeps Biopharma Inc. (KOSDAQ:256940) Stock Yet As It Plummets 27%

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have retraced a considerable 27% in the last month, reversing a fair...
Analysis Article Jun 17

Market Participants Recognise Keeps Biopharma Inc.'s (KOSDAQ:256940) Revenues Pushing Shares 43% Higher

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 43% gain in the last month...
Analysis Article May 15

Is Keeps Biopharma (KOSDAQ:256940) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Apr 18

Further Upside For Keeps Biopharma Inc. (KOSDAQ:256940) Shares Could Introduce Price Risks After 33% Bounce

Keeps Biopharma Inc. ( KOSDAQ:256940 ) shares have continued their recent momentum with a 33% gain in the last month...
Analysis Article Feb 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) 33% Share Price Climb

The KPS Corporation ( KOSDAQ:256940 ) share price has done very well over the last month, posting an excellent gain of...
Analysis Article Jan 13

KPS (KOSDAQ:256940) Takes On Some Risk With Its Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Dec 06

A Piece Of The Puzzle Missing From KPS Corporation's (KOSDAQ:256940) Share Price

There wouldn't be many who think KPS Corporation's ( KOSDAQ:256940 ) price-to-sales (or "P/S") ratio of 0.7x is worth a...
Analysis Article Mar 31

KPS (KOSDAQ:256940) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for KPS Corporation's ( KOSDAQ:256940 ) stock hasn't moved much. We...
Analysis Article Feb 26

Sentiment Still Eluding KPS Corporation (KOSDAQ:256940)

With a median price-to-sales (or "P/S") ratio of close to 1.8x in the Semiconductor industry in Korea, you could be...

Shareholder Returns

A256940KR SemiconductorKR Market
7D-2.7%-11.8%-8.2%
1Y-60.6%585.2%159.6%

Return vs Industry: A256940 underperformed the KR Semiconductor industry which returned 585.2% over the past year.

Return vs Market: A256940 underperformed the KR Market which returned 159.6% over the past year.

Price Volatility

Is A256940's price volatile compared to industry and market?
A256940 volatility
A256940 Average Weekly Movement10.5%
Semiconductor Industry Average Movement13.7%
Market Average Movement9.3%
10% most volatile stocks in KR Market16.5%
10% least volatile stocks in KR Market4.9%

Stable Share Price: A256940 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A256940's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000109Young Kim Hawww.kpscorp.co.kr/kps/index.php

Keeps Biopharma Inc. engages in the research, development, production, and sale of mechanical equipment for manufacturing flat panel displays in South Korea, China, and internationally. It offers OLED equipment, inspection technologies, camera modules, precision systems, and TSP/solar products. The company is also involved in bio research and development business; waste battery recycling; and other non-ferrous metal smelting, refining, and alloy manufacturing.

Keeps Biopharma Inc. Fundamentals Summary

How do Keeps Biopharma's earnings and revenue compare to its market cap?
A256940 fundamental statistics
Market cap₩128.70b
Earnings (TTM)-₩9.79b
Revenue (TTM)₩170.15b
0.8x
P/S Ratio
-13.2x
P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A256940 income statement (TTM)
Revenue₩170.15b
Cost of Revenue₩132.57b
Gross Profit₩37.58b
Other Expenses₩47.36b
Earnings-₩9.79b

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-487.36
Gross Margin22.08%
Net Profit Margin-5.75%
Debt/Equity Ratio113.0%

How did A256940 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 23:54
End of Day Share Price 2026/05/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Keeps Biopharma Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
YoungSik YoonShinhan Investment Corp.
Sun-Jae HeoSK Securities Co., Ltd.